Disease · MONDO_0010383
Trials52
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 52
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03614663 | Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) | Phase 2/3 | 212 | 2022-06-16 | Fragile X Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01348087 | Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome | Phase 2 | 148 | 2016-05-25 | Fragile X Syndrome | MAVOGLURANT | Its record names the disease | ClinicalTrials.gov |
| NCT01357239 | Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome | Phase 2 | 139 | 2015-05-12 | Fragile X Syndrome | MAVOGLURANT | Its record names the disease | ClinicalTrials.gov |
| NCT01433354 | Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) | Phase 2/3 | 119 | 2015-10-12 | Fragile X Syndrome | MAVOGLURANT | Its record names the disease | ClinicalTrials.gov |
| NCT02920892 | AFQ056 for Language Learning in Children With FXS | Phase 2 | 110 | 2023-10-10 | Fragile X Syndrome | MAVOGLURANT | Its record names the disease | ClinicalTrials.gov |
| NCT01053156 | Trial of Minocycline to Treat Children With Fragile X Syndrome | Not applicable | 66 | 2014-07-30 | Fragile X Syndrome | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT01725152 | Ganaxolone Treatment in Children With Fragile X Syndrome | Phase 2 | 59 | 2023-04-10 | Fragile x Syndrome | GANAXOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT01474746 | Trial of Sertraline to Treat Children With Fragile X Syndrome | Phase 2 | 57 | 2017-09-25 | Fragile X Syndrome | SERTRALINE | Its record names the disease | ClinicalTrials.gov |
| NCT01120626 | Randomized Controlled Study of Donepezil in Fragile X Syndrome | Phase 2 | 45 | 2016-03-17 | Fragile X Syndrome | DONEPEZIL | Its record names the disease | ClinicalTrials.gov |
| NCT03697161 | A Study of OV101 in Individuals With Fragile X Syndrome | Phase 2 | 36 | 2024-01-23 | Fragile X Syndrome (FXS) | GABOXADOL | Its record names the disease | ClinicalTrials.gov |
| NCT03569631 | A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome | Phase 2 | 30 | 2024-12-19 | Fragile X Syndrome, FXS, Fra(X) Syndrome | ZATOLMILAST | Its record names the disease | ClinicalTrials.gov |
| NCT02998151 | Neurophysiological and Acute Pharmacological Studies in FXS Patients | Early phase 1 | 29 | 2021-11-24 | Fragile X Syndrome | ACAMPROSATE, BACLOFEN, LOVASTATIN, MINOCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT00858689 | Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome | Not applicable | 20 | 2016-02-18 | Fragile X Syndrome | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT05030129 | ERG/5-HTP in Fragile X Syndrome (FXS) | Phase 2 | 15 | 2024-09-19 | Fragile X Syndrome | ERGOLOID MESYLATES, OXITRIPTAN | Its record names the disease | ClinicalTrials.gov |
| NCT01300923 | Acamprosate in Youth With Fragile X Syndrome | Phase 2 | 14 | 2017-04-28 | Fragile X Syndrome, Autism Spectrum Disorders | ACAMPROSATE | Its record names the disease | ClinicalTrials.gov |
| NCT00420459 | A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome | Phase 2 | 12 | 2017-04-18 | Fragile X Syndrome | ARIPIPRAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01254045 | Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome | Phase 2 | 10 | 2014-08-29 | Fragile X Syndrome | OXYTOCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03802799 | Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | Phase 2/3 | 476 | Fragile X Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT01555333 | An Open Label Extension Study in Subjects With Fragile X Syndrome | Phase 3 | 357 | Fragile X Syndrome | ARBACLOFEN | Its record names the disease | ClinicalTrials.gov | |
| NCT05367960 | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | Phase 3 | 314 | Fragile X Syndrome | ZATOLMILAST | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010383/trials